Measure ID
ABX-03-C
Description

Percentage of adult patients undergoing an open cardiac procedure with an antibiotic redose initiated within four hours after initial antibiotic administration (cephalosporins only).

Measure Type
Process
Available for Provider Feedback
Yes
Threshold
90%
Rationale

Surgical site infections are associated with significant morbidity and mortality.1-4 Administration of on-time antibiotic prophylaxis redosing is one mechanism to prevent surgical site infections.1-4

Measure Time Period

120 minutes before Anesthesia Start through Surgery End. If Surgery End is not available, Anesthesia End.

Inclusions
  • Adult patients undergoing open cardiac surgical procedures (determined by Procedure Type: Cardiac: value code 1) and receiving antibiotic prophylaxis with a cephalosporin.
Exclusions
  • Age < 18 years
  • ASA 6 including Organ Procurement (CPT: 01990)
  • Cases where Surgery End time occurs before redose is due (less than 4 hours and 15 minutes after cephalosporin dose)
  • Cases without administration of a cephalosporin for antibiotic prophylaxis
  • Lung transplants
  • Non-cardiac, Transcatheter/Endovascular, EP/Cath, and Other Cardiac cases (determined by the Procedure Type: Cardiac value codes: 0, 2, 3, and 4)
  • Patients already on scheduled antibiotics or had a documented infection prior to surgery as determined by “Patient on Scheduled Antibiotics/Documented Infection” of ABX Notes
Success Criteria

Documentation of cephalosporin re-dose within 180-255 minutes after each cephalosporin administration.

For longer cases, a second re-dose within 180-255 minutes after initial re-dose is required unless the last cephalosporin dose is ≤255 minutes before Surgery End. If Surgery End is not available, Anesthesia End.

Other Measure Details

Acceptable Antibiotics and Associated Timing:

Antibiotic MPOG Concept ID
Cefamandole 10106
Cefazolin 10107
Cefepime 10108
Cefotaxime 10109
Cefotetan 10110
Cefoxitin 10111
Ceftazidime 10112
Ceftizoxime 10113
Ceftriaxone 10114
Cefuroxime 10115

 

  • Only doses administered via IV route (MPOG Concept ID: 2001) will be considered.
  • Any case where an antibiotic listed in the table above was not re-dosed within 180-255 minutes will be flagged unless there is ≤ 255 minutes between a cephalosporin dose and Surgery End (re-dose not required). If Surgery End is not available, Anesthesia End will be used.
  • Maximum number of doses per case is three: 1 initial and up to two re-dose administrations.  
  • If cephalosporin administration was documented as an infusion, infusion start time will be used to determine timing for re-dose. If the infusion is still running at time of re-dose, case will pass. 
  • Measure will only look for the prophylactic variance note (as determined by the ABX Notes Phenotype) if an antibiotic re-dose is not documented within the appropriate time frame. If note returns ‘scheduled antibiotics/documented infection’ - case will be excluded. 
  • Cases will be assigned one of the following results:
    • Passed - Re-dose(s) administered on time
    • Flagged - Antibiotic re-dose too late
    • Flagged - Antibiotic re-dose too early
    • Flagged - Antibiotic re-dose required but not given
    • Excluded - Scheduled antibiotics/documented infection
    • Excluded - No initial cephalosporin dose
    • Excluded - Re-dose not required
    • Excluded - ASA 6
    • Excluded - Non-Cardiac
    • Excluded - Age<18

*This measure will include valid MPOG cases defined by the Is Valid Case phenotype.

Risk Adjustment

Not applicable

Provider Attribution

Provider(s) signed in at the time of each re-dose (If not given: 255 minutes after initial cephalosporin dose, and/or if not given: 255 minutes after the first re-dose).

MPOG Concept Used
  • 10106 Cefamandole
  • 10107 Cefazolin
  • 10108 Cefepime
  • 10109 Cefotaxime
  • 10110 Cefotetan
  • 10111 Cefoxitin
  • 10112 Ceftazidime
  • 10113 Ceftizoxime
  • 10114 Ceftriaxone
  • 10115 Cefuroxime
  • 50181 Compliance - Prophylactic antibiotic variance note 
  • 50182 Compliance - Prophylactic antibiotic variance detail
  • 50622 Compliance - Antibiotic Started
MPOG Phenotypes Used
References
  1. Surat G, Bernsen D, Schimmer C: Antimicrobial stewardship measures in cardiac surgery and its impact on surgical site infections. J Cardiothorac Surg 2021; 16:309
  2. Bratzler DW, Dellinger EP, Olsen KM, Perl TM, Auwaerter PG, Bolon MK, Fish DN, Napolitano LM, Sawyer RG, Slain D, Steinberg JP, Weinstein RA, American Society of Health-System Pharmacists (ASHP), Infectious Diseases Society of America (IDSA), Surgical Infection Society (SIS), Society for Healthcare Epidemiology of America (SHEA): Clinical practice guidelines for antimicrobial prophylaxis in surgery. Surg Infect 2013; 14:73–156
  3. Bardia A, Michel G, Farela A, Fisher C, Mori M, Huttler J, Lang AL, Geirsson A, Schonberger RB: Association of adherence to individual components of Society of Thoracic Surgeons cardiac surgery antibiotic guidelines and postoperative infections. J Thorac Cardiovasc Surg 2023 doi:10.1016/j.jtcvs.2023.03.031
  4. Engelman R, Shahian D, Shemin R, Guy TS, Bratzler D, Edwards F, Jacobs M, Fernando H, Bridges C; Workforce on Evidence-Based Medicine, Society of Thoracic Surgeons. The Society of Thoracic Surgeons practice guideline series: Antibiotic prophylaxis in cardiac surgery, part II: Antibiotic choice. Ann Thorac Surg. 2007 Apr;83(4):1569-76. doi: 10.1016/j.athoracsur.2006.09.046. PMID: 17383396.
Measure Authors
 Measure Author  Institution
 Mike Mathis, MD  University of Michigan
 Allison Janda, MD  University of Michigan
 Kate Buehler, MS, RN  University of Michigan
 Bethany Pennington, PharmD, BCPS  Washington University
 Henrietta Addo, MSN-NI, RN  University of Michigan
 Rob Coleman  University of Michigan
MPOG Cardiac Anesthesia Subcommittee
Measure Reviewer(s)
Next Review: 2027
 Date Reviewed  Reviewer  Institution  Summary  QC Vote
         

 

Version
Published: 2024
Date Criteria Revision
1/23/2024   Initial Publication